Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution-NoDerivatives 4.0 Internationalhttps://creativecommons.org/licenses/by-nd/4.0/Tarih
2016Yazar
Başaran, ÖzcanDoğan, Volkan
Beton, Osman
Tekinalp, Mehmet
Aykan, Ahmet Cağrı
Kalaycıoğlu, Ezgi
Bolat, İsmail
Taşar, Onur
Şafak, Özgen
Kalcık, Macit
Yaman, Mehmet
İnci, Sinan
Altıntaş, Bernas
Kalkan, Sedat
Kırma, Cevat
Biteker, Murat
Karadeniz Özpamuk, Fatma
Tekkesin, Ahmet İlker
Çakıllı, Yasin
Türkkan, Ceyhan
Hamidi, Mehmet
Demir, Vahit
Gürsoy, Mustafa Ozan
Öztürk Tek, Müjgan
Aksan, Gökhan
Seyis, Sabri
Ballı, Mehmet
Alıcı, Mehmet Hayri
Bozyel, Serdar
Altun, İbrahim
Çalık, Feyza
Karaca, Oğuz
Helvacı, Füsun
Akay, Kadriye
Canga, Yiğit
Çelebi, Savaş
Altuntaş, Emine
Aytürk, Mehmet
Güneş, Hacı Murat
Bezgin, Tahir
Aksakal, Aytekin
Çakal, Beytullah
Çolak, Ayşe
Kaplan, Özgür
Tatlısu, Adem
Gözübüyük, Gökhan
Demirelli, Selami
Kaya, Adnan
Rencuzoğullari, İbrahim
Bayram, Zübeyde
Şimsek, Zeki
Civan, Murat
Batgharel, Ulaankhu
Ata, Ali Ekber
Göl, Gökhan
Mert, Gurbet Özge
Mert, Kadir Uğur
Değirmencioğlu, Aleks
Candan, Özkan
Çelebi, Özlem Özcan
Doğan, Cem
Yavuz, Fethi
Ulucan, Şeref
Arısoy, Arif
Şahin, Bingül Dilekçi
Ermiş, Emrah
Gökaslan, Serkan
Pektaş, İdris
Tanındı, Aslı
Tekin, Kamuran
Sancar Memiç, Kadriye
Çekic, Edip Güvenç
Başaran, Nesrin Filiz
Üst veri
Tüm öğe kaydını gösterKünye
Başaran, Ö., Doğan, V., Beton, O., Tekinalp, M., Aykan, A. Ç., Kalaycıoğlu, E. ... Başaran, N. F. (2016). Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study. Medicine, 95(35). https://dx.doi.org/10.1097/MD.0000000000004672Özet
This study aimed to investigate the potential misuse of novel oral anticoagulants (NOACs) and the physicians' adherence to current European guideline recommendations in real-world using a large dataset from Real-life Multicenter Survey Evaluating Stroke Prevention Strategies in Turkey (RAMSES Study).RAMSES study is a prospective, multicenter, nationwide registry (ClinicalTrials.gov identifier NCT02344901). In this subgroup analysis of RAMSES study, patients who were on NOACs were classified as appropriately treated (AT), undertreated (UT), and overtreated (OT) according to the European Society of Cardiology (ESC) guidelines. The independent predictors of UT and OT were determined by multivariate logistic regression.Of the 2086 eligible patients, 1247 (59.8%) received adequate treatment. However, off-label use was detected in 839 (40.2%) patients; 634 (30.4%) patients received UT and 205 (9.8%) received OT. Independent predictors of UT included >65 years of age, creatinine clearance 50mL/min, urban living, existing dabigatran treatment, and HAS-BLED score of <3, whereas that of OT were creatinine clearance <50mL/min, ongoing rivaroxaban treatment, and HAS-BLED score of 3.The suboptimal use of NOACs is common because of physicians' poor compliance to the guideline recommendations in patients with nonvalvular atrial fibrillation (NVAF). Older patients who were on dabigatran treatment with good renal functions and low risk of bleeding were at risk of UT, whereas patients who were on rivaroxaban treatment with renal impairment and high risk of bleeding were at risk of OT. Therefore, a greater emphasis should be given to prescribe the recommended dose for the specified patients.
WoS Q Kategorisi
Q3Scopus Q Kategorisi
Q2Kaynak
MedicineCilt
95Sayı
35Koleksiyonlar
- Makale Koleksiyonu [3649]
- PubMed İndeksli Yayınlar Koleksiyonu [4047]
- Scopus İndeksli Yayınlar Koleksiyonu [6283]
- WoS İndeksli Yayınlar Koleksiyonu [6432]
İlgili Öğeler
Başlık, yazar, küratör ve konuya göre gösterilen ilgili öğeler.
-
Guideline-adherent therapy for stroke prevention in atrial fibrillation in different health care settings: Results from ramses study
Başaran, Özcan; Doğan, Volkan; Biteker, Murat; Karadeniz Özpamuk, Fatma; Tekkesin, Ahmet İlker; Çakıllı, Yasin; Türkkan, Ceyhan; Hamidi, Mehmet; Demir, Vahit; Gürsoy, Mustafa Ozan; Öztürk, Müjgan Tek; Aksan, Gökhan; Seyis, Sabri; Ballı, Mehmet; Alıcı, Mehmet Hayri; Bozyel, Serdar; Kırma, Cevat; Beton, Osman; Tekinalp, Mehmet; Aykan, Ahmet Çağrı; Kalaycıoğlu, Ezgi; Bolat, İsmail; Taşar, Onur; Şafak, Özgen; Kalçık, Macit; Yaman, Mehmet; İnci, Sinan; Altıntaş, Bernas; Kalkan Semih; Çalık, Feyza; Karaca, Oğuz; Helvacı, Füsun; Akay Halli, Kadriye; Çanga, Yiğit; Çelebi, Savaş; Altuntaş, Emine; Aytürk, Mehmet; Güneş, Hacı Murat; Bezgin, Tahir; Aksakal, Aytekin; Çakal, Beytullah; Çolak, Ayşe; Kaplan, Özgür; Tatlısu, Adem; Gözübüyük, Gökhan; Demirelli, Selami; Kaya, Adnan; Rencüzoğulları, İbrahim; Bayram, Zübeyde; Şimşek, Ziya; Civan, Murat; Batgharel, Ulaankhu; Ata, Ali Ekber; Göl, Gökhan; Mert Gurbet Özge; Mert, Kadir Uğur; Değirmencioğlu, Aleks; Candan, Özkan; Çelebi Özcan, Özlem; Doğan, Cem; Yavuz, Fethi; Ulucan, Şeref; Arısoy, Arif; Şahin Dilekçi, Bingül; Ermiş, Emrah; Gökaslan, Serkan; Pektaş, İdris; Tanındı, Aslı; Tekin, Kamuran; Sancar Memiç, Kadriye; Çekiç, Edip Güvenç; Başaran, Filiz Nesrin; Altun, İbrahim (Elsevier B.V., 2017)Objective No studies have been conducted in Turkey to compare the quality of stroke prevention therapies provided in different healthcare settings in patients with atrial fibrillation (AF). Therefore, we aimed to evaluate ... -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Sönmez, Mehmet Giray; Gülbaş, Zafer; Tekgündüz, Emre; Kaya, Ali Hakan; Özbalak, Murat; Taştemir, N; Kaynar, Leylagül; Yildirim Rahşan; Karadoğan, İhsan; Arat Ersöz, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abali, Hüseyin; Turgut, Mehmet; Kurt Yüksel, M; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Barişta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Toprak, Selami Koçak; Yilmaz, Mehmet Birhan; Demirkürek, Hüseyin; Demirkol, Mehmet Onur; Ferhanoğlu, Burhan (Oxford University Press, 2017)Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, ... -
Demographics of patients with heart failure who were over 80 years old and were admitted to the cardiology clinics in Turkey
Gök, Gülay; Zoghi, Mehdi; Sinan, Ümit Yaşar; Kılıç, Salih; Tokgözoğlu, Lale; Sümerkan, Mutlu Çağan; Emren, Volkan; Bekar, Lütfü; Cerşit, Sinan; Tunç, Elif; Ulucan, Şeref; Altuntaş, Emine; Canpolat, Uğur; Özmen, Namık; Açıksarı, Gönül; Doğan, Nazile Bilgin; Günay, Şeyda; Kemaloğlu, Meltem Didem; Nacar, Alper Buğra; Karakoyun, Süleyman; İnci, Sinan; Özlek, Bülent; Aslan, Onur; Baykız, Derya; Gündüz, Sabahattin; Köroğlu, Sedat; Helvacı, Ayşen; Coşkun, Raşit; Yüksel, İsa Öner; Çetin, Şükrü; Yesin, Mahmut; Gürsoy, Mustafa Ozan; Çatırlı Enar, Sibel; Tek Öztürk, Müjgan; Yılmaz, Aykut; Başaran, Özcan; Okyay, Kaan; Öztürk, Cengiz; Çelik, Oğuzhan; Yalçınkaya, Emre; Aslan, Vedat; Şenol, Utku; Uçar, Fatih Mehmet; Kozluca, Volkan; Türkoğlu, Ebru İpek; Şekuri, Cevat; Ertürk, Mehmet; Altun, İbrahim; Belen, Erdal; Aksan, Gökhan; Yıldırım, Erkan; Sayın, Ahmet; Akkoyun, Dursun Çayan; Tunçez, Abdullah; Doğan, Volkan; Gürel, Yusuf Emre; Demirelli, Selami; Koca, Çiğdem; Biteker, Murat; Bas, Hasan Aydın; Güzet, Feza; Taçoy, Gülten; Alpsoy, Şeref; Turan, Turhan; Davutoğlu, Vedat; Birdane, Alparslan; Onrat, Ersel; Baha, Mehmet Reşat; Yılmaz, Sabiye; Altay, Servet; Alıcı, Mehmet Hayri; Özcan, İsmail Türkay; Kuş, Görkem; Demir, Gültekin Günhan; Sancar, Kadriye Memiç; Demirçelik, Muhammed Bora; Yanık, Ahmet; Akciğer, Atike Nazlı; Hoşcan, Yeşim; Arslan, Kürşat; Otlu, Yılmaz Ömür; Şahin, İsmail; Ersoy, İbrahim; YIlmaz, Dilek Çiçek; Mert, Kadir Uğur; Varim, Perihan; Arı, Hatem (Turkish Society of Cardiology, 2019)Objective: Heart failure (HF) has a high prevalence and mortality rate in elderly patients; however, there are few studies that have focused on patients older than 80 years. The aim of this study is to describe and compare ...